Want to see AU:PER full AI Analyst Report?
PER Stock Chart & Stats
AU$0.01
>-AU$0.01(-25.00%)
At close: 4:00 PM EDT
AU$0.01
>-AU$0.01(-25.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume5.97M
Average Volume (3M)2.49M
Market Cap
AU$7.61M
Enterprise Value-AU$1.17
Total Cash (Recent Filing)AU$4.05M
Total Debt (Recent Filing)AU$27.79K
Price to Earnings (P/E)―
Beta0.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,522,415,500
10 Day Avg. Volume2,742,659
30 Day Avg. Volume2,485,493
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces interest and refinancing pressure, giving Percheron greater financial flexibility as it advances its clinical programs. This limits balance-sheet risk, although it does not remove the need for funding while the company remains pre-commercial.
Improved Cash OutflowThe reduction in cash outflow indicates some improvement in near-term cost management and cash preservation. If sustained, this could extend the company’s funding runway and support continued development activity while it works toward clinical and regulatory milestones.
Focused Clinical Development PlatformA focused pipeline in serious neurological and neuromuscular diseases provides a defined strategic direction and potential access to high-need markets. Continued clinical and regulatory progress could create long-term value if candidates demonstrate safety and efficacy.
Bears Say
No Revenue BaseThe absence of revenue confirms that Percheron has not yet established a commercial product base or recurring operating income. This leaves results dependent on development progress and external capital until a candidate can be approved and commercialized.
Persistent Cash BurnRecurring negative operating and free cash flow means the business consumes cash rather than funding itself. Unless revenue begins to materialize, continued clinical development will likely require additional financing, creating dilution and execution risk.
Sustained Losses And Equity ErosionPersistent losses are reducing the capital base and weakening financial resilience despite low debt. The company remains far from breakeven, so prolonged development timelines or setbacks could accelerate equity erosion and increase reliance on external funding.
Percheron Therapeutics News
PER FAQ
What was Percheron Therapeutics’s price range in the past 12 months?
Percheron Therapeutics lowest share price was <AU$0.01 and its highest was AU$0.01 in the past 12 months.
What is Percheron Therapeutics’s market cap?
Percheron Therapeutics’s market cap is AU$7.61M.
When is Percheron Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Percheron Therapeutics’s earnings last quarter?
Currently, no data Available
Is Percheron Therapeutics overvalued?
According to Wall Street analysts Percheron Therapeutics’s price is currently Overvalued.
Does Percheron Therapeutics pay dividends?
Percheron Therapeutics does not currently pay dividends.
What is Percheron Therapeutics’s EPS estimate?
Percheron Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics have?
Percheron Therapeutics has 1,522,415,500 shares outstanding.
What happened to Percheron Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Percheron Therapeutics?
Currently, no hedge funds are holding shares in AU:PER
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Percheron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.10%
Trailing 12-Months
Company Description
Percheron Therapeutics
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
Technical Analysis
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Cronos Australia Ltd.
―